Neurobiological Intersections: The Synergistic Role of Neuroinflammation and HPA Axis Dysregulation in Adolescent-Onset Depression

Abstract

Adolescent-onset major depressive disorder (MDD) emerges during a critical neurodevelopmental window, with incidence rising sharply from 2% at age 13 to over 17% by age 18, driven by synergistic interactions between hypothalamic-pituitary-adrenal (HPA) axis dysregulation and neuroinflammation. This review integrates immunopsychiatric perspectives, highlighting HPA hyperactivity marked by elevated basal cortisol, glucocorticoid receptor resistance, altered cortisol awakening response (CAR), and feedback failure as a core feature exacerbated by early-life adversity (abuse leading to steeper CAR). Neuroinflammation, mediated by M1-polarized microglia and pro-inflammatory cytokines (IL-6, TNF-α, CRP), depletes serotonin via the kynurenine pathway, induces excitotoxicity, and disrupts synaptic plasticity. Bidirectional crosstalk amplifies pathology: cytokines sensitize the HPA axis, while glucocorticoids promote glial activation and blood-brain barrier permeability. Impacts on frontolimbic circuits include hippocampal atrophy, prefrontal hypoactivity, and amygdala hyperreactivity, with sex-specific vulnerabilities (estrogen-mediated inflammation in females). Therapeutic avenues encompass anti-inflammatory agents (e.g., NSAIDs, minocycline), lifestyle interventions (diet, exercise), and microbiome modulation to restore balance. This framework underscores the need for early, integrated interventions to mitigate long-term neurobiological and clinical sequelae in vulnerable youth.